AKT1 and adenocarcinoma: Using H460 (large cell lung carcinoma) and A549 (adenocarcinoma) cell lines, both characterized by constitutive activation of PI3K/AKT, we systematically evaluated Cisplatin, 5-fluorouracil (5-FU), and small molecule inhibitors (SMIs) of AKT (MK2206) and PI3K (BKM120).